Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$11.78 - $13.86 $1.92 Million - $2.26 Million
163,250 Added 12.31%
1,489,025 $18.1 Million
Q2 2023

Aug 11, 2023

SELL
$10.72 - $13.3 $1.44 Million - $1.79 Million
-134,400 Reduced 9.2%
1,325,775 $16.7 Million
Q1 2023

May 12, 2023

BUY
$10.91 - $13.54 $345,847 - $429,218
31,700 Added 2.22%
1,460,175 $16.2 Million
Q4 2022

Feb 13, 2023

SELL
$9.89 - $12.7 $2.57 Million - $3.3 Million
-259,925 Reduced 15.39%
1,428,475 $17.4 Million
Q3 2022

Nov 10, 2022

SELL
$9.82 - $12.75 $3.17 Million - $4.11 Million
-322,500 Reduced 16.04%
1,688,400 $17.6 Million
Q2 2022

Aug 12, 2022

BUY
$6.23 - $11.12 $12.5 Million - $22.4 Million
2,010,900 New
2,010,900 $21.6 Million

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.49B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Finepoint Capital LP Portfolio

Follow Finepoint Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.